Evaluating Microarray Pharmacogenetic Testing in Cancer Patients

Launched by WAKE FOREST UNIVERSITY HEALTH SCIENCES · Jul 3, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a special test called microarray pharmacogenetic testing (or PGx testing) to see how it can help doctors choose the right medications and dosages for cancer patients, particularly those with gastrointestinal cancers. This test is meant for patients who are already eligible for a standard single-gene test related to their treatment. The goal is to improve the effectiveness of cancer treatments by using this advanced testing approach.

To participate in the study, you need to be at least 18 years old and able to provide consent for your health information to be shared. You should also be set to receive a specific type of chemotherapy that uses fluoropyrimidines, which are common drugs for treating cancer. If you join the study, you may need to provide some additional saliva samples if the initial DNA tests do not provide enough information. It's important to note that people who have had certain types of organ transplants cannot take part in this trial. If you are interested and meet these criteria, you could contribute to important research that may help improve cancer treatment for others in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Written informed consent and HIPAA authorization for release of personal health information.
• • Age ≥ 18 years at the time of consent.
• • Eligible for standard of care single-gene DPYD testing (i.e., receiving or expected to receive a fluoropyrimidine-based chemotherapy regimen). The potential participant meets inclusion criteria if the standard of care single-gene DPYD test is planned or previously ordered. If previously ordered, consent must occur no later than 60 days from the date the DPYD results were available.
• • Willing to provide additional buccal swabs if residual DNA from previous DPYD testing is inadequate for microarray testing.
• Exclusion Criteria:
• • • History of prior allogeneic hematopoietic cell transplantation or liver transplantation